Before you buy a single tablet, it is worth understanding why 7-OH is so much stronger than the plant material it comes from. This post explains the mechanism in plain language — and what it means for how you should dose.
The receptor story
Kratom contains several alkaloids, the two you will hear most about being mitragynine and 7-hydroxymitragynine (7-OH). Both interact with opioid receptors in the brain, but 7-OH binds with far greater affinity. In practical terms, that means the biological effect per milligram is dramatically higher — which is the entire reason concentrated 7-OH products exist and the entire reason dosing precision matters. Our mitragynine vs 7-OH comparison covers the numbers.
What happens after you chew a tablet
Chewing (rather than swallowing whole) speeds up breakdown and absorption. Most users report onset within roughly 15–45 minutes, with peak effects somewhere between the first and third hour and a total duration that commonly lands around 2–5 hours depending on dose and individual factors. A chewable format also avoids the GI irritation that swallows powders can cause. The full timeline by strength is in onset & duration by strength.
Why dose is the variable that matters
Because receptor activity is dose-dependent, the difference between “a little too much” and “about right” is measured in milligrams, not “a bit more powder.” This is why our tablets are uniform and breakable into halves and quarters: a 60mg tablet gives you 15mg pieces, and a 10mg tablet gives you 2.5mg pieces. The dosing basics post shows exactly how to use that.
Tolerance is part of the picture
Repeated activation of opioid receptors leads to tolerance — you need more for the same effect — and some users develop physical dependence. This is not a scare tactic; it is the mechanism, and it is the reason responsible-use habits (planned low-dose windows, no daily escalation) are non-negotiable. See how tolerance builds and what experienced users do differently.
What the research does — and does not — say
Human clinical research on 7-OH specifically is limited. What is established: it is a potent opioid-receptor agonist in lab models, its affinity exceeds mitragynine’s, and it carries the standard risks of that class (dependence, respiratory depression at high doses, dangerous interactions with other depressants). There are no FDA-approved uses and no medical claims to make here.
If you understand the mechanism, the product decisions get easier: precise strength, small first dose, no mixing with other depressants. Start with the 180mg entry range, and keep the FAQ handy for anything else.